During the past decade, Zhang Xiaodong conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Zhang Xiaodong" are "Advanced Esophageal Carcinoma" (2 trials) and "Advanced Esophageal Squamous Carcinoma" (1 trials). Many other conditions were trialed in "Zhang Xiaodong" in a lesser frequency.

Most popular intervention types in "Zhang Xiaodong" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "irinotecan/cisplatin" (1 trials), "mFOLFIRI" (1 trials) and "mFOLFIRI+Nimotuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Zhang Xiaodong" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Zhang Xiaodong". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Zhang Xiaodong, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Zhang Xiaodong, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".